autosomal dominant retinitis pigmentosa (Applied Genetic Technologies)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameautosomal dominant retinitis pigmentosa (Applied Genetic Technologies)
Drug Alias NamerAAV2/5-MOP-RHO310-siRNA301
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionRhodopsin modulators
TargetsRhodopsin
Therapy Area/IndicationsRetinitis Pigmentosa
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBeacon Therapeutics Holdings Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBeacon Therapeutics Holdings Ltd
Active IndicationsN/A
Inactive IndicationsRetinitis Pigmentosa

Other Information

ATC CodeN/A
Related LinksN/A